The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
Open Access
- 27 June 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (1) , 27-34
- https://doi.org/10.1038/sj.bjc.6603215
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The impact of workload changes and staff availability on IV chemotherapy servicesJournal of Oncology Pharmacy Practice, 2003
- Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluationHealth Technology Assessment, 2003
- Epidemiology, treatment and chemoprevention in colorectal cancerAnnals of Oncology, 2003
- Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialThe Lancet, 2003
- A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in CanadaPharmacoEconomics, 2003
- Capecitabine as first-line treatment in colorectal cancerEuropean Journal Of Cancer, 2002
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal Of Cancer, 2002
- ABC of colorectal cancer: Treatment of advanced diseaseBMJ, 2000
- Attitudes and practice in the management of metastatic colorectal cancer in BritainClinical Oncology, 1997
- Pharmacoeconomic Evaluation of Tegafur-Uracil (UFT) vs Fluorouracil for the Management of Colorectal Cancer in Brazil and ArgentinaClinical Drug Investigation, 1997